Cardiome Reports Fourth Quarter and Full Year 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- S&P 500, Nasdaq slip as Iran tensions test markets in high-stakes week
- Oil falls ahead of US announcement of new sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- S&P 500, Nasdaq slip as Iran tensions test markets in high-stakes week
- RUM Group signs $13.7 billion GPU services deal, issues warrants
- XPeng Inc. (XPEV) Misses Q2 EPS by 100c ; Provides Outlook
- Hungarian Gripen jet crashes, no injuries reported, PM Magyar says
Cardiome Pharma (CRME) Misses Q4 EPS by 6c
March 13, 2018 4:01 PM EDTCardiome Pharma (NASDAQ: CRME) reported Q4 EPS of ($0.24), $0.06 worse than the analyst estimate of ($0.18). Revenue for the quarter came in at $7 million versus the consensus estimate of $8.23 million.
For earnings history and earnings-related data on Cardiome Pharma (CRME) click here.
... More